OPKO Health, Inc. (OPK)

Nasdaq: OPK · Pharmaceutical Preparations · Miami, FL · filing with the SEC since 1996

Full chart Alerts Compare

Grade5.2

◀ Past 5.3● Present 6.2▶ Future 3.9

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$607M-14.9%

Net income-$226M-324.0%

Earnings per share$-0.30-275.0%

Operating cash flow-$179M+2.7%

Cash$364M-14.6%

Debt$2.3M-24.7%

Shareholders’ equity$1.27B-7.1%

Shares, diluted751.1M+8.2%

Return on equity-17.8%

The recordfrom its filings

Filings in 202634

Newest filingNov 6 · SCHEDULE 13D/A

Annual reportFeb 26, 2026

Quarterly reportNov 4, 2026

Next report due10-K by Mar 16

Insider sales, 12 months$0.00

Insider buys, 12 months$3.0M

Patents granted266

Filer categoryAccelerated filer

Trailing twelve months to Sep 2026Revenue $801MNet income -$148MCash from operations -$125Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 6, 2026 · SEC EDGAR · Form SCHEDULE 13D/A

Activist holder update, amended

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Oct 15, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 2, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 28, 2026 · SEC EDGAR · Form 10-Q/A

Quarterly report, amended

Open the filing on sec.gov

Aug 28, 2026 · SEC EDGAR · Form 10-Q/A

Quarterly report, amended

Open the filing on sec.gov

Aug 14, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 7, 2026 · SEC EDGAR · Form SCHEDULE 13D

Activist holder notice

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

OPKO Health, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Miami, FL. Service was 61% of fiscal 2025 revenue.

Newest on the record

Activist holder update, amended on Nov 6. Before it, insider trade report on Nov 5.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 16, 2027.

About OPK

OPKO Health, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Miami, FL. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $607 million and a loss of $226 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersMiami, FL

Business modelProduct business

ExchangeNasdaq

Filing since1996

Fiscal year endsDec 31

SEC number (CIK)944809

Peers on fileHCM, ARWR, LEGN, COLL

Who runs it

Financial performance

In fiscal 2025 OPKO Health’s revenue was $606.9 million, down 14.9% from $713.1 million the year before. It made a net loss of $225.7 million.

Annual report, filed Feb 26, 2026.

Financial statements

The grade

OPKO Health grades 5.2 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past5.3

● Present6.2

▶ Future3.9

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton OPK · research, not advice